Coronavirus biology and replication: implications for SARS-CoV-2

2020/10/28 by Philip V’kovski, Annika Kratzel, Silvio Steiner +2 · 27 citations
Medicine · #COVID-19 Clinical Research Studies #SARS-CoV-2 and COVID-19 Research #Viral gastroenteritis research and epidemiology

paper · pdf · doi:10.1038/s41579-020-00468-6

crossref issued 2020/10/28 · crossref published 2020/10/28 · crossref published-online 2020/10/28 · openalex publication_date 2020/10/28 · crossref created 2020/10/28 · openalex created_date 2020/11/09 · crossref published-print 2021/03/01 · crossref deposited 2023/05/20 · openalex updated_date 2026/07/30 · crossref indexed 2026/07/30

Citations

• Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis
• Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
• A Novel Coronavirus from Patients with Pneumonia in China, 2019
• A new coronavirus associated with human respiratory disease in China
• A pneumonia outbreak associated with a new coronavirus of probable bat origin
• Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro
• Pathological findings of COVID-19 associated with acute respiratory distress syndrome
• Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses
• Clinical Characteristics of Coronavirus Disease 2019 in China
• Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein
• The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2
• SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
• Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2
• Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors
• Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV
• Structural basis of receptor recognition by SARS-CoV-2
• Virological assessment of hospitalized patients with COVID-2019
• Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor
• Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors
• Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19
• The Architecture of SARS-CoV-2 Transcriptome
• Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
• The trinity of COVID-19: immunity, inflammation and intervention
• Host-Viral Infection Maps Reveal Signatures of Severe COVID-19 Patients
• A SARS-CoV-2 protein interaction map reveals targets for drug repurposing
• Cell entry mechanisms of SARS-CoV-2
• Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19
• Neuropilin-1 is a host factor for SARS-CoV-2 infection

Cited by

• A lung-specific mutational signature enables inference of viral and bacterial respiratory niche
• COVID-19 disease and autoimmune disorders: A mutual pathway
• Discovery of the Clinical Candidate <b>S-892216</b> : A Second-Generation of SARS-CoV-2 3CL Protease Inhibitorfor Treating COVID-19
• Antiviral effect of Bromelain combined with acetylcysteine against SARS-CoV-2 Omicron variant
• Unraveling the relevance of SARS-Cov-2 infection and ferroptosis within the heart of COVID-19 patients
• Promising Schiff bases in antiviral drug design and discovery
• Loss of host factor-mediated m ⁶ Am methylation of the viral RNA cap impairs SARS CoV-2 replication
• Unbiased cleavage site prediction uncovers viral antagonism of host innate immunity by SARS-CoV-2 3C-like protease
• Silencing of SARS‐CoV‐2 with modified siRNA‐peptide dendrimer formulation
• Unleashing the Antiviral Potential of Stapled Peptides: A New Frontier in Combating Human Neurotropic Viral Infections
• The role of intrinsically disordered regions of SARS-CoV-2 nucleocapsid and non-structural protein 1 proteins
• The zymogenic form of SARS-CoV-2 main protease: A discrete target for drug discovery
• Risk Impact of SARS-CoV-2 Coronavirus and Spike Protein on Cardiac Tissue: A Comprehensive Review
• Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of Nsp14 RNA cap methyltransferase
• Mass spectrometric assays monitoring the deubiquitinase activity of the SARS-CoV-2 papain-like protease inform on the basis of substrate selectivity and have utility for substrate identification
• Copper(II) benzyloxychalcone analogues as new potential metallodrugs against SARS-CoV-2 replication
• Pox-AbDab: the orthopoxvirus antibody database
• Highly Recurrent Multinucleotide Mutations in SARS-CoV-2
• <i>In silico</i> discovery of novel quinazolin-4-one derivatives as potent 3CLpro inhibitors using 2D-QSAR, molecular docking, and molecular dynamics
• Development of SARS-CoV-2 as a viral vector: A novel intranasal bivalent vaccine for SARS-CoV-2 and RSV
• SARS-CoV-2 remodels the Golgi apparatus to facilitate viral assembly and secretion
• Long COVID or Post-acute Sequelae of COVID-19 (PASC): An Overview of Biological Factors That May Contribute to Persistent Symptoms
• Cephalosporins are potent SARS-CoV-2 main protease inhibitors
• Ordinary differential equation models of SARS-CoV-2 replication dynamics and antiviral drug efficacies
• Viral proteases as therapeutic targets
• SARS-CoV-2 predation of Golgi-bound PI4P primes the massive activation of the DNA Damage Response kinase ATM in the cytoplasm
• An oral non-covalent non-peptidic inhibitor of SARS-CoV-2 Mpro ameliorates viral replication and pathogenesis in vivo
• Psychodietetics: Food As the Key to Emotional Health